For many Americans, wound care therapy made possible by Medicare reimbursements means the difference between life and death. Those reimbursements are now the target of Medicare contractors more interested in saving money than they are in saving lives.
As currently proposed, the policy [known as the Local Coverage Determination (LCD) “Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers.”] would drastically affect the care provided to patients in the future, and result in treatment that falls glaringly short of clinical standards.
Eliminating coverage of over 200 skin substitute products, this arbitrary and inconsistent proposal would immediately trigger a shortage, leaving tens of thousands of Medicare beneficiaries without treatment and facing sepsis, amputation, and ultimately death.